Recent licenses and collaborations
Rowett has a long history of licensing technology
from its research. We have a robust approach to establishing and
maintaining IP protection to help potential licensees optimise their
due diligence procedures. Technologies currently available for licensing
or for co-development can be found by clicking here (link).
There is no simple formula for licensing and the precise
terms will depend on the technology and the company. Rowett prides
itself on a flexible approach to licensing to assist early commercial
development and would be pleased to discuss any opportunities in
more detail. You can contact us by clicking here or via our contact
page.
Below are some examples of licenses that have been
concluded in recent years which illustrate the breadth of the technologies
available.
Therapeutics
Alizyme plc (www.alizyme.com)
Alizyme is a specialist developer of therapies for gut disorders,
Obesity and Mucositis based in Cambridge. Alizyme is taking a new
approach to the treatment of mucositis involving ATL-104, which
it acquired from Rowett and which stimulates the growth of the cells
lining the mouth and gastrointestinal tract ('the mucosa'). ATL-104
is a plant protein that is manufactured in a recombinant process
and was selected for clinical development in order to ensure a consistent
supply of product. During cancer treatments involving chemotherapy
and radiotherapy, damage to the mucosa can result in mucositis,
which is painful, can prevent eating and can cause diarrhoea, malnutrition
and systemic infections. It can also limit the intensity of cancer
treatment and affect the quality of life of between 15% and 40%
patients. There is no drug currently available that can effectively
prevent or treat mucositis. The Phase I and IIa clinical development
programmes for ATL 104 have recently been successfully completed.
In parallel to the technology agreement Rowett has continue to provide
specialist expertise to support the preclinical development phase.
Diagnostics
Quidel Corporation (www.quidel.com)
is a worldwide leader in developing, manufacturing and marketing
point-of-care (POC) rapid diagnostic tests for the detection and
management of a variety of medical conditions and illnesses based
in San Diego. In the US the company leads the market in several
POC product categories for sales through medical product distributors
Their products aim to provide healthcare professionals with accurate
and cost-effective diagnostic information at the POC and focus on
women's and family health in areas including pregnancy, infectious
diseases, general health screening, bone health and autoimmune disorders.
Quidel now markets worldwide under a technology agreement the Metra®PYD
and Metra®DPD kits developed originally at Rowett by Dr Simon
Robins for measurement of collagen resorption.
Life Science Tools
Haptogen Limited (www.haptogen.com)
is fast growing biopharmaceutical company, based in Aberdeen which
in January 2006 was named as one of the top 10 new businesses in
Scotland . It has unique antibody generation capabilities founded
on a proprietary technology platform - Haptomics and is developing
therapeutic antibodies against a range of novel drug targets beyond
the reach of other immunotechnologies. As part of this it has developed
it’s DNA Binding Domain Display Expression System (DBDx™)
Technology based on technology developed at the Rowett and licensed
to the company. DBDx™ has the ability of certain steroid hormone
receptors to bind with high affinity and absolute specificity to
particular single stranded DNA sequences. It differs from conventional
phage display as presentation of proteins is achieved at the viral
particle surface without the requirement for viral coat protein
gene fusion or signal sequence to target expression to the phage
surface. The DBDx™ system is more flexible and provides a
more efficient system, increasing functional library sizes and displayed
repertoire diversity.
Rowett science has also been licensed to each of our
spin out companies and more details of these can be found by following
the link
|
